IMO-2055
- Generic Name
- IMO-2055
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 847484-35-9
- Unique Ingredient Identifier
- 8566421Q5R
- Indication
Investigated for use/treatment in renal cell carcinoma, solid tumors, and lung cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT00729053
- Locations
- ๐บ๐ธ
Georgetown University, Lombardi Cancer Center, Washington, District of Columbia, United States
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 21
- Registration Number
- NCT00719199
- Locations
- ๐บ๐ธ
Georgetown University Lombardi Cancer Center, Washington, DC, District of Columbia, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธVanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 36
- Registration Number
- NCT00633529
- Locations
- ๐บ๐ธ
Mary Crowley Medical Research Center, Dallas, Texas, United States
๐บ๐ธCentral Indiana Cancer Centers, Indianapolis, Indiana, United States
๐บ๐ธCancer Therapy and Research Center, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath